Sanofi and IONTAS have signed an agreement through which the company will use IONTAS’ proprietary technology – which aims to bridge the gap between a “great lead” and “poor developability,” says CBO.
Concept Life Sciences has teamed up with the UK-based bioanalytical contract research organization (CRO) Alderley Analytical to provide customers with bioanalytical and DMPK study services.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Charles River Laboratories has acquired KWS BioTest in a deal that will expand the company’s immunology contract research services and geographical footprint.
ChemDiv and the German Center for Neurodegenerative Diseases (DZNE) have launched a pre-commercial translational R&D program with support from Torrey Pines Investment.
Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.
KMT Hepatech is expanding its services with the PXB-Mouse – a humanized liver chimeric mouse model for drug discovery and development – following a strategic investment from PhoenixBio late last year.
Specialty reagent provider Maravai LifeSciences has acquired Glen Research Corporation to provide more comprehensive solutions to its customers, says VP.
JSR Corporation has acquired Crown Bioscience for more than $405m – the company’s largest investment to date as it turns its attention towards preclinical support for biopharma, says Life Sciences president.
Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.
The National Institutes of Health (NIH) has created a new clinical trials consortium with a model focused on streamlining research and diverse recruitment.
Only eight of the top 40 CROs are Privacy Shield Framework-certified, says Science Exchange CEO as the company continues to rack up partnerships with pharma companies looking to streamline outsourcing efforts and mitigate risk.
By Sudip S. Parikh, PhD, senior vice president & managing director, DIA Americas
The healthcare product development ecosystem is undergoing massive changes. Significant transformations are underway in how drugs and medical devices are researched, developed, manufactured, and approved.
It is an “exciting time in drug discovery,” says Charles River CSO as the company expands its CRISPR/Cas9 service offering with a license from ERS Genomics.
Ncardia is ‘moving up the value chain’ as it shifts from a product-focused company to a preclinical contract research organization (CRO) and grows in size – and clout, says VP.
Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.
Pharmaceutical companies should share their outsourcing strategy across the company in order to ensure success, says panel discussing the benefits and challenges of working with contract organizations.
ATCC has released an in vitro model system for a key mechanism of invasion and metastasis in lung cancer as the company continues its efforts to provide drug discovery and development services.
A Chinese regulatory institute has opened a non-animal testing laboratory – a model for regulatory bodies to show that implementing alternative methods into government laboratories is achievable, says IIVS president.
Boehringer Ingelheim has launched a new platform through which it will offer open access to selected preclinical molecules in order to 'unlock the full potential' of compounds no longer under development by the company.
The Tri-Institutional Therapeutics Discovery Institute, Inc. will use ChemDiv's proprietary discovery chemistry platform to advance its research and development (R&D) pipeline.
Sotera Health – the recently rebranded Sterigenics International – will add extractables and leachables testing services to its Nelson Labs business with the acquisition of Toxikon Europe NV.
Advanced imaging in drug discovery aims to improve the success rate of drug development as the industry continues to tackle devastating diseases such as Alzheimer’s – but no research lab can do it alone, says Charles River managing director.
AMRI’s SSCI has announced the availability of in vitro bioequivalence testing services, as more products entering the market require laboratory-based testing.
Horizon Discovery and The Michael J. Fox Foundation have introduced two new preclinical models for Parkinson’s Disease research – including a first-of-its-kind model that will help researchers understand the biology behind a mutation linked to the disease.
Charles River is extending its preclinical services through a partnership with InSphero AG – “further affirmation” of its commitment to the in vitro oncology space, says executive director.
EDASA Scientific has partnered with Namiki Shoji Co., a Japanese company distributing drug discovery compounds and intermediates to the pharmaceutical industry.
Concept Life Sciences has acquired Aquila BioMedical, citing the CRO’s specific skill set, which will allow the company to provide services in areas “not previously accessible,” says executive chairman.
Fraunhofer is “redoubling” its efforts to develop new antibiotics and transfer research into clinical trials through a project available to external partners for development.
AMRI is offering its impurity solutions as a stand-alone service in response to new regulatory requirements that set limits for the amounts of elemental impurities in drug products.
BioMoti and Pharmidex have received funding to advance proof-of-concept precision medicine studies – which if successful, could help secure pharma partnerships or additional investment, says BioMoti CEO.
ShangPharma Innovation and SRI International are collaborating to develop treatments for neurodegenerative and inflammatory conditions, such as Alzheimer’s disease.
BTS research has been recommended for AAALAC full accreditation at their new facility, which recently came under fire for reported violations of the federal Animal Welfare Act.
Cullinan Oncology has launched with $150m in funding, a focus on risk, and a business model through which it will rely on a global network of third-party vendors, says CEO.
The People for the Ethical Treatment of Animals (PETA) is looking to send a researcher to learn about non-animal test methods – adoption of which it says is slowed by regulatory agency acceptance.
Pharma and diagnostic partners will gain access to a human cancer biospecimens and clinical data from patients to power clinical and translational research, says CRO.
